Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas

Inclusion Criteria: * Patients with metastatic and/or advanced solid tumors or lymphomas not amenable to curative treatment by surgery. * Histologically documented advanced or metastatic solid tumors or lymphomas * Must have a site of disease amenable to biopsy, and be a candidate for tumor biopsy according to the treating institution's guidelines. Patient must be willing to undergo a new tumor biopsy at screening * ECOG Performance Status ≤ 2. Exclusion Criteria: * Presence of symptomatic central nervous system (CNS) metastases, or CNS metastases that require local CNS-directed therapy (such as radiotherapy or surgery). * Patients diagnosed with T-cell Lymphomas. * Patients with prior allogenic transplants. * Patients previously treated with anti-GITR therapy. * History of severe hypersensitivity reactions to other mAbs. * Patients intolerant to prior immunotherapy (unable to continue/receive due to immune-related AE). Other protocol-defined inclusion/exclusion criteria may apply.